Mydayis

Narcolepsy, Depression, Attention Deficit Hyperactivity Disorder + 1 more
Treatment
2 FDA approvals
20 Active Studies for Mydayis

What is Mydayis

Amphetamine/DextroamphetamineThe Generic name of this drug
Treatment SummaryAmphetamine is a strong stimulant drug that was discovered over 100 years ago. It is heavily regulated and only used for a few specific medical conditions. It is made up of two chemical compounds, alpha-methylphenethylamine, and has two forms of the same molecule (dextro- and levo-isomers). The first product of the drug was approved by the FDA in 1976. During World War II, amphetamine was used to keep soldiers awake, which led to an overproduction of it and its eventual sale on the black market.
Adderallis the brand name
image of different drug pills on a surface
Mydayis Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Adderall
Amphetamine/Dextroamphetamine
1996
507

Approved as Treatment by the FDA

Amphetamine/Dextroamphetamine, also known as Adderall, is approved by the FDA for 2 uses such as Narcolepsy and Attention Deficit Hyperactivity Disorder .
Narcolepsy
Attention Deficit Hyperactivity Disorder
Used to treat Attention Deficit Hyperactivity Disorder (ADHD) in combination with Dextroamphetamine

Effectiveness

How Mydayis Affects PatientsAmphetamine increases levels of the brain chemicals noradrenaline and dopamine in a dose-dependent way, which can cause cardiovascular side effects. It has been reported to improve intelligence test scores, behavior and school performance in those with ADHD. It is commonly used in a 3:1 ratio of D:L forms. Amphetamine has a less clear effect on serotonin but could help with the depression and anxiety associated with ADHD. Taking amphetamine illicitly has been linked to paranoid states and misuse in those with depression.
How Mydayis works in the bodyAmphetamine has a similar structure to catecholamine neurotransmitters and is taken into the presynaptic nerve terminals by attaching to three ions. This causes more amphetamine to be internalized. The amphetamine then competes with the other neurotransmitters, forcing them out of the presynaptic terminal and into the synapse. This process of release is more effective in the d-isomer form. In addition to this, amphetamine also inhibits the reuptake and monoamine oxidase, which increases the concentration of neurotransmitters. Lastly, amphetamine is a weak monoamine oxidase inhibitor which helps

When to interrupt dosage

The quantity of Mydayis is contingent upon the determined disease, such as Disease, Chronic Pain and Attention Deficit Hyperactivity Disorder. The measure of dosage fluctuates as per the method of administration (e.g. Oral or Tablet - Oral) featured in the table beneath.
Condition
Dosage
Administration
Attention Deficit Hyperactivity Disorder
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Chronic Pain
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Narcolepsy
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Depression
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Mydayis has eight contraindications, making it inadvisable to use when encountering any of the conditions in the subsequent table.Mydayis Contraindications
Condition
Risk Level
Notes
Agitation
Do Not Combine
advanced arteriosclerosis
Do Not Combine
Drug abuse
Do Not Combine
Hyperthyroidism
Do Not Combine
Hypertensive disease
Do Not Combine
symptomatic cardiovascular disease
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Amphetamine/Dextroamphetamine may interact with Pulse Frequency
There are 20 known major drug interactions with Mydayis.
Common Mydayis Drug Interactions
Drug Name
Risk Level
Description
Clonidine
Major
The metabolism of Clonidine can be decreased when combined with Amphetamine.
Cyclophosphamide
Major
The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.
Dacomitinib
Major
The metabolism of Dacomitinib can be decreased when combined with Amphetamine.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Amphetamine.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Amphetamine.
Mydayis Toxicity & Overdose RiskThe average lethal dose of amphetamine is 6.4 mg/l. Taking too much of this drug can cause a dangerously high body temperature, impaired breathing, acid buildup in the body, kidney failure, liver damage, and loss of consciousness. Other symptoms may include agitation, aggression, extreme irritability, headaches, and hallucinations. There may also be problems with the heart such as an irregular heartbeat, heart damage, a heart attack, or a stroke. Additionally, amphetamine can cause abdominal pain, vomiting, diarrhea, cramps, anorexia, and bleeding in the digestive tract. Very high doses of 1-2g can be
image of a doctor in a lab doing drug, clinical research

Mydayis Novel Uses: Which Conditions Have a Clinical Trial Featuring Mydayis?

Currently, 710 active studies are exploring the potential of Mydayis to ameliorate symptoms of Depression, Disease and Narcolepsy.
Condition
Clinical Trials
Trial Phases
Narcolepsy
2 Actively Recruiting
Not Applicable, Phase 1
Attention Deficit Hyperactivity Disorder
63 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2
Chronic Pain
0 Actively Recruiting
Depression
305 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Mydayis Reviews: What are patients saying about Mydayis?

5Patient Review
9/25/2018
Mydayis for Attention Deficit Disorder with Hyperactivity
I've found that the instant release version of this medication works better for me. It kicks in faster and lasts longer than Mydayis, which only provides relief for about eight hours. With instant release, I don't have to worry as much about side effects, either.
3.7Patient Review
6/11/2019
Mydayis for Attention Deficit Disorder with Hyperactivity
The medication does help with my focus and ADD symptoms, However, the aftermath of taking it can be really tough. It suppresses my appetite which is great for weight loss but sometimes I go days without eating which isn't so great. Not sure if its the dosage or what, since I had similar issues when taking Adderall.
1.7Patient Review
12/13/2019
Mydayis for Attention Deficit Disorder with Hyperactivity
I am very agitated and anxious on this new medication Mydayis, upsets my stomach. I will be switching back to Adderall it is what worked for me and I didn't have those horrible side effects definitely helped me to focus 100 X better than Mydayis .
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about mydayis

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Mydayis a narcotic?

"Advise patients not to share MYDAYIS with others and to take steps to protect it from theft.

Controlled Substance Status/High Potential For Abuse And Dependence. Advise patients and their caregivers that MYDAYIS is a federally controlled substance because it has a high potential for abuse and dependence. Advise patients not to share MYDAYIS with others and to take steps to protect it from theft."

Answered by AI

Is Mydayis the same as Adderall?

"Both Mydayis and Adderall are central nervous system stimulants used to treat ADHD. However, Mydayis is formulated to last up to 16 hours, while Adderall only lasts for 12 hours."

Answered by AI

Can you get high off Mydayis?

"Mydayis is a Schedule II drug. It is highly addictive and has a high potential for abuse, like other amphetamines. Other Schedule II drugs include morphine and Vicodin. People abuse the drug for its pleasurable high."

Answered by AI

Which is better Vyvanse or Mydayis?

"There is no direct clinical comparative study between Mydayis and Vyvanse drugs, however, both drugs have been shown to be effective in treating ADHD in both adults and children in separate studies. Mydayis is used to treat children aged 13 years and older, while Vyvanse is used to treat children aged 6 years and older."

Answered by AI

Clinical Trials for Mydayis

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA
The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical CenterScott Irwin, MD
Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.
Phase 1
Recruiting
St. Jude Children's Research HospitalAndrew Heitzer, PhD
Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA
The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.
Waitlist Available
Has No Placebo
University of California San Diego
Have you considered Mydayis clinical trials? We made a collection of clinical trials featuring Mydayis, we think they might fit your search criteria.Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL
The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.
Waitlist Available
Has No Placebo
Virtual/ No Physical FacilityCandice S Rasa, LCSW
Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA
The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.
Phase 2
Recruiting
University of California, Los Angeles
Have you considered Mydayis clinical trials? We made a collection of clinical trials featuring Mydayis, we think they might fit your search criteria.Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Image of Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth College in Lebanon, United States.

Advertising Claims for Anxiety and Depression

18+
All Sexes
Lebanon, NH
In the U.S., legal cannabis is frequently advertised as an effective treatment for mental health problems such as anxiety and depression-particularly online. States that have legalized cannabis have not implemented regulations to address this type of advertising. This project aims to investigate the influence of psychotherapeutic advertising claims (PAC) and mental health warning labels (WL) on online cannabis purchasing behaviors among light-to-moderate cannabis users with symptoms of depression and/or anxiety. The specific aims are to determine whether PAC increases cannabis purchasing intentions and whether a mental health WL can mitigate this effect. A realistic online cannabis shopping experience will be simulated using the digital Platform for Online Evaluation of Marijuana Marketing and Sales (POEMMS). The study will employ a between-subjects experimental design by randomizing 2,000 participants to one of four online stores that vary in PAC and WL content: (1) a control claims (CC)-only store, (2) a PAC store, (3) a WL store, and (4) a PAC + WL store. Participants will browse and select items as if making real purchases. Analyses will examine three primary outcomes to determine the influence of PAC and WL on purchasing behaviors: (1) total milligrams of THC purchased, (2) average potency (%THC) of products, and (3) overall number of products purchased. The long-term objective is to inform evidence-based cannabis policy and regulatory strategies by understanding the impact of cannabis marketing on vulnerable populations. This research is relevant to public health by addressing the potential risks associated with misleading cannabis marketing, which may lead to increased use and exacerbation of mental health symptoms among individuals with depression and anxiety. The project leverages a multidisciplinary team with expertise in addiction, mental health, epidemiology, and digital health technology. The findings have the potential to inform the development of targeted interventions and policies to reduce harms associated with cannabis advertising-ultimately contributing to better health outcomes and more effective regulation.
Waitlist Available
Has No Placebo
Center for Technology and Behavioral Health (CTBH), Geisel School of Medicine at Dartmouth CollegeJames Sargent, MD
Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)
Recruiting
Device
UCSF Nancy Friend Pritzker Psychiatry Building
Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX
The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.
Waitlist Available
Online Trial
The University of Texas at Austin
Have you considered Mydayis clinical trials? We made a collection of clinical trials featuring Mydayis, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security